Galmed Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Business Update

Published: Nov 08, 2016

TEL AVIV, Israel, Nov. 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and liver diseases, today reported financial results for the three and nine months ended September 30, 2016. The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for AramcholTM.

Back to news